August 25, 2010
Bioniche & University of Ottawa Sign Exclusive Global License Agreement for Natural Health Technology

August 20, 2010
Additional Phase III Clinical Trial with UrocidinTM Expected to Commence in 2010

Check latest
stock price

All prices delayed at least 15 minutes.
Source: TSX Inc.

Corporate News Release

Bioniche to Present at Rodman & Renshaw 8th Annual Healthcare Conference

31/10/06

BELLEVILLE, ON, October 31, 2006 – Bioniche Life Sciences Inc. (TSX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced that Graeme McRae, President & CEO, is scheduled to present at the Rodman & Renshaw 8th Annual Global Healthcare Conference, November 6-8 in New York City. Mr. McRae will present on Monday, November 6th at 4:35 p.m. (Eastern Time) in the Kennedy II Room.

A live webcast of Bioniche’s presentation can be accessed here. A replay of the presentation will be archived for 90 days after the conference, at the same locations. For more information about the Rodman & Renshaw 8th Annual Healthcare Conference, please visit Rodman & Renshaw's website.

Bioniche Life Sciences received approval from the U.S. Food and Drug Administration (FDA) for two Phase III clinical trials using the Company’s proprietary Mycobacterial Cell Wall-DNA Complex (MCC) – trademarked Urocidin - for the treatment of bladder cancer.

In the first part of the Phase III program, 105 patients will be involved in an open-label study showing the efficacy of Urocidin as therapy in superficial bladder cancer refractory (unresponsive) to Bacillus Calmette-Guérin (BCG). BCG is a live, attenuated strain of Mycobacterium bovis, the current standard therapy for bladder cancer, but one that is often associated with treatment-limiting side effects. This study will be conducted in North America. The FDA granted this study Fast Track designation in April. With this designation, Bioniche expects an expedited review following completion of the study.

The Company expects to start its second Phase III clinical trial — comparing Urocidin to BCG in treatment-naive non-muscle invasive bladder cancer patients (first line therapy) — in 2007. This study will involve more than 600 patients in North America and Europe. It is expected that this study will demonstrate that Urocidin is superior to BCG in terms of safety and is at least as efficacious.

About Urocidin (MCC)

Mycobacterial Cell Wall-DNA Complex (MCC) is formulated from Mycobacterium phlei, a non-pathogenic strain of mycobacteria. MCC has been shown to have immune stimulatory and apoptosis (programmed cell death) activity against cancer cells. The product is a sterile biological composition in a sub-micron suspension. Urocidin is produced at the Bioniche manufacturing facility in Pointe-Claire, Québec.

Back

Categories:
All Releases
Archived Releases
Animal Health
Corporate
Financial
Food Safety
Human Health